Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2019

View Archived Issues

Malaria vaccine has indirect protective effects

ActoBio Therapeutics announces IND approval for AG-017 for the treatment of celiac disease

Oral HRI activator EPB-53 improves glucose intolerance through FGF21

Experiments reveal the role of GDNF in intestinal epithelial barrier dysfunction in IBD

Study of RAC1 P29S mutation in melanoma points to target for reversing BRAF inhibitor resistance

Aerie initiates first-in-human study of AR-13503 sustained-release intravitreal Implant

First patient dosed in global phase II study of BT-11 in mild to moderate ulcerative colitis

Synlogic discontinues development of SYNB-1020 for the treatment of hyperammonemia

PI3K-alpha tested as a therapeutic target for prevention of heterotopic ossification

Novel mannosylated nanovaccines sensitize melanoma to immune checkpoint modulators

The other end of APP

Vertex Pharmaceuticals, Merck Patent disclose eIF-2-alpha kinase GCN2 inhibitors

More evidence links Schwann cells to pain

Sinovent discovers beta-lactamase inhibitors

Tau imagining agents patented by AC Immune, Life Molecular Imaging

Blastocyst-like embryonic structure grown from stem cells

ST Pharm presents new antivirals

New cyclin-dependent kinase 4/6 inhibitors identified at Beta Pharma

Phase III NEPTUNE study does not meet primary endpoint in patients with high TMB

Mersana Therapeutics initiates expansion portion of phase I trial of XMT-1536

First patient enrolled in observational study of children and adolescents with Dravet syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...